Search Count: 7
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Release Date: 2025-08-20 Classification: HYDROLASE/INHIBOTOR Ligands: A1L7M |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR Ligands: A1L7M |
 |
Discovery Of An Orally Bioavailable Reversible Covalent Sars-Cov-2 Mpro Inhibitor With Pan-Coronavirus Activity
Organism: Severe acute respiratory syndrome coronavirus 2, Synthetic construct
Method: X-RAY DIFFRACTION Release Date: 2025-08-20 Classification: HYDROLASE/INHIBITOR Ligands: A1L7M |
 |
Strategic Design Of Catalytic Lysine-Targeting Reversible Covalent Bcr-Abl Inhibitors
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.72 Å Release Date: 2021-06-09 Classification: TRANSFERASE Ligands: FVC |
 |
Strategic Design Of Catalytic Lysine-Targeting Reversible Covalent Bcr-Abl Inhibitors
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:2.30 Å Release Date: 2021-06-09 Classification: TRANSFERASE Ligands: HJ9 |